FBIOP
Income statement / Annual
Last year (2023), Fortress Biotech, Inc.'s total revenue was $84.51 M,
an increase of 11.58% from the previous year.
In 2023, Fortress Biotech, Inc.'s net income was -$60.64 M.
See Fortress Biotech, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$84.51 M
|
$75.74 M
|
$68.79 M
|
$45.60 M
|
$36.63 M
|
$26.88 M
|
$187.58 M
|
$16.48 M
|
$863,000.00
|
$0.00
|
| Cost of Revenue |
$26.66 M |
$30.78 M |
$32.08 M |
$14.59 M |
$10.53 M |
$6.13 M |
$161.20 M |
$11.35 M |
$0.00 |
$0.00 |
| Gross Profit |
$57.85 M |
$44.97 M |
$36.71 M |
$31.01 M |
$26.10 M |
$20.76 M |
$26.38 M |
$5.13 M |
$863,000.00 |
$0.00 |
| Gross Profit Ratio |
0.68 |
0.59 |
0.53 |
0.68 |
0.71 |
0.77 |
0.14 |
0.31 |
1 |
0 |
| Research and Development
Expenses |
$106.07 M
|
$134.88 M
|
$128.87 M
|
$64.11 M
|
$81.33 M
|
$87.38 M
|
$52.49 M
|
$35.13 M
|
$29.81 M
|
$10.24 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$55.59 M
|
$53.37 M
|
$73.02 M
|
$35.16 M
|
$21.58 M
|
$10.41 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$155.19 M
|
$10.41 M
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$94.12 M
|
$113.66 M
|
$86.84 M
|
$61.17 M
|
$55.59 M
|
$53.37 M
|
$73.02 M
|
$35.16 M
|
$21.58 M
|
$10.41 M
|
| Other Expenses |
$0.00 |
-$1.30 M |
$25.17 M |
$2.83 M |
$6.09 M |
$68,000.00 |
-$234,000.00 |
-$9.87 M |
$11.41 M |
$0.00 |
| Operating Expenses |
$200.20 M |
$247.23 M |
$215.71 M |
$125.28 M |
$136.92 M |
$140.75 M |
$127.59 M |
$70.84 M |
$51.39 M |
$20.65 M |
| Cost And Expenses |
$226.86 M |
$278.00 M |
$247.79 M |
$139.87 M |
$147.45 M |
$146.88 M |
$288.79 M |
$82.19 M |
$51.39 M |
$20.65 M |
| Interest Income |
$3.00 M |
$1.40 M |
$649,000.00 |
$1.52 M |
$2.56 M |
$1.10 M |
$819,000.00 |
$298,000.00 |
$245,000.00 |
$662,000.00 |
| Interest Expense |
$11.92 M |
$13.64 M |
$15.31 M |
$9.70 M |
$11.85 M |
$10.34 M |
$5.86 M |
$3.69 M |
$1.48 M |
$1.34 M |
| Depreciation &
Amortization |
$8.08 M
|
$9.35 M
|
$6.79 M
|
$5.33 M
|
$4.65 M
|
$2.06 M
|
$1.26 M
|
$728,000.00
|
$26,000.00
|
$23,000.00
|
| EBITDA |
-$133.64 M
|
-$190.47 M
|
-$142.25 M
|
-$87.82 M
|
-$85.16 M
|
-$118.40 M
|
-$88.57 M
|
-$66.87 M
|
-$52.37 M
|
-$20.63 M
|
| EBITDA Ratio |
-1.58 |
-2.65 |
-2.59 |
-2.04 |
-2.83 |
-4.34 |
-0.53 |
-3.9 |
-58.27 |
0 |
| Operating Income Ratio
|
-1.68
|
-2.67
|
-2.6
|
-2.07
|
-3.03
|
-4.46
|
-0.54
|
-3.99
|
-58.55
|
0
|
| Total Other
Income/Expenses Net |
-$11.29 M
|
-$9.90 M
|
$24.19 M
|
-$8.58 M
|
$9.16 M
|
-$10.80 M
|
-$7.72 M
|
-$5.58 M
|
-$3.35 M
|
$266,000.00
|
| Income Before Tax |
-$153.63 M |
-$213.46 M |
-$164.35 M |
-$102.85 M |
-$101.66 M |
-$130.80 M |
-$98.32 M |
-$71.29 M |
-$53.88 M |
-$20.39 M |
| Income Before Tax Ratio
|
-1.82
|
-2.82
|
-2.39
|
-2.26
|
-2.78
|
-4.87
|
-0.52
|
-4.33
|
-62.44
|
0
|
| Income Tax Expense |
$521,000.00 |
$449,000.00 |
$473,000.00 |
$136,000.00 |
-$49.85 M |
-$463,000.00 |
$1.51 M |
-$12.51 M |
-$4.00 M |
$1.32 M |
| Net Income |
-$60.64 M |
-$213.91 M |
-$164.83 M |
-$102.99 M |
-$51.81 M |
-$84.15 M |
-$66.88 M |
-$55.10 M |
-$48.43 M |
-$20.39 M |
| Net Income Ratio |
-0.72 |
-2.82 |
-2.4 |
-2.26 |
-1.41 |
-3.13 |
-0.36 |
-3.34 |
-56.12 |
0 |
| EPS |
-8.47 |
-36.1 |
-30.26 |
-21.45 |
-14.2 |
-29.04 |
-24.08 |
-20.68 |
-18.56 |
-8.42 |
| EPS Diluted |
-8.47 |
-36.1 |
-30.26 |
-21.45 |
-14.2 |
-29.04 |
-24.08 |
-20.68 |
-18.56 |
-8.42 |
| Weighted Average Shares
Out |
$8.11 M
|
$5.92 M
|
$5.45 M
|
$4.80 M
|
$3.65 M
|
$2.90 M
|
$2.78 M
|
$2.66 M
|
$2.61 M
|
$2.42 M
|
| Weighted Average Shares
Out Diluted |
$8.11 M
|
$5.92 M
|
$5.45 M
|
$4.80 M
|
$3.65 M
|
$2.90 M
|
$2.78 M
|
$2.66 M
|
$2.61 M
|
$2.42 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
